Seedline Bulk API Supply, home
Peptides

Peptide APIs, each listed with its FDA status.

Sermorelin, gonadorelin and oxytocin are in 503B Category 1. Most other peptides here have no 503B pathway, and each line says so.

Price-check one itemRequest the supplier file
Three glass vials of white lyophilized powder held in a stainless steel rack

Read before ordering

  • None of the peptides on this page is on FDA's 503B bulks list.
  • For 503A pharmacies: HHS published a draft enforcement policy on Oct 30, 2026 for six peptides in specific forms and routes (BPC-157 acetate, TB-500 acetate, Epitalon acetate, MOTS-c acetate, KPV acetate, Semax free base). It is a draft and nonbinding, it doesn't cover 503B facilities, and it has 10 conditions. See For 503A pharmacies.
  • Items FDA treats as biologics (proteins over 40 amino acids) are labeled not compoundable.

What we list (53)

503B Category 1 FDA interim policy, conditions applyCategory 2 FDA safety risk, outside the interim policyBiologic not eligible for 503A/503B compoundingWithdrawn list not for human compoundingNo 503B pathway not on the bulks list, the shortage list or in Category 1503A HHS draft policy formVeterinary animal compounding

Status as of Nov 14, 2026. Sources: FDA 503B categories list (updated Mar 21, 2025), FDA Category 2 page (current Apr 22, 2026), 21 CFR 216.24, 21 CFR 530.41, 21 CFR 600.3(h)(6), HHS FR 2026-22192. No item we list is on the 503B bulks list today. Shortage status is checked when we price your request. Labels are a starting point, not a determination for your facility.

  • Gonadorelin Acetate 503B Category 1Price this item
  • Oxytocin 503B Category 1Price this item
  • Sermorelin Acetate 503B Category 1Price this item
  • Acetyl Hexapeptide-3 Acetate No 503B pathwayPrice this item

    503B Category 3 (nominated without adequate support).

  • ACTH 1-24 (Tetracosactide Acetate) No 503B pathwayPrice this item
  • AOD-9604 Acetate No 503B pathwayPrice this item

    FDA previously listed safety concerns (nomination withdrawn from Category 2).

  • ARA290 (Cibinetide) Acetate No 503B pathwayPrice this item
  • BPC-157 Acetate No 503B pathway 503A: HHS draft policyPrice this item

    503A: covered by the HHS draft six-peptide policy (Oct 30, 2026) in the acetate form, by the listed routes, if all 10 conditions are met. Draft, nonbinding.

  • BPC-157 Base No 503B pathwayPrice this item

    Outside the HHS 503A draft policy (acetate form only).

  • Bremelanotide Acetate No 503B pathwayPrice this item
  • CB4211 Acetate No 503B pathwayPrice this item

    Not found in FDA’s 503B category list; status to be verified.

  • CJC-1295 Acetate No 503B pathwayPrice this item

    FDA previously listed safety concerns (nomination withdrawn from Category 2).

  • Delta Sleep Inducing Peptide (DSIP) Acetate No 503B pathwayPrice this item

    FDA previously listed safety concerns (nomination withdrawn from Category 2).

  • Deslorelin Acetate No 503B pathway VeterinaryPrice this item
  • Desmopressin Acetate Trihydrate No 503B pathwayPrice this item
  • Dihexa Acetate No 503B pathwayPrice this item

    FDA previously listed safety concerns (nomination withdrawn from Category 2).

  • Epithalon Acetate No 503B pathway 503A: HHS draft policyPrice this item

    503A: covered by the HHS draft six-peptide policy (Oct 30, 2026) in the acetate form, by the listed routes, if all 10 conditions are met. Draft, nonbinding.

  • FOXO-4 DRI Acetate No 503B pathwayPrice this item
  • GHK Acetate No 503B pathwayPrice this item
  • GHK-Cu Acetate No 503B pathwayPrice this item
  • Hexarelin Acetate No 503B pathwayPrice this item
  • Histrelin Acetate No 503B pathwayPrice this item
  • Humanin Acetate No 503B pathwayPrice this item
  • iRGD Acetate No 503B pathwayPrice this item
  • KCF-18 Acetate No 503B pathwayPrice this item
  • Kisspeptin-10 Acetate No 503B pathwayPrice this item

    503A: Category 2 (FDA safety risk).

  • KPV Acetate No 503B pathway 503A: HHS draft policyPrice this item

    503A: covered by the HHS draft six-peptide policy (Oct 30, 2026) in the acetate form, by the listed routes, if all 10 conditions are met. Draft, nonbinding.

  • Leuprolide Acetate No 503B pathwayPrice this item
  • LL-37 Acetate No 503B pathwayPrice this item

    FDA previously listed safety concerns (nomination withdrawn from Category 2).

  • Melanotan I Acetate No 503B pathwayPrice this item
  • Melanotan II Acetate No 503B pathwayPrice this item

    FDA previously listed safety concerns (nomination withdrawn from Category 2).

  • Met-Enkephalin Acetate No 503B pathwayPrice this item
  • MOTs-C Acetate No 503B pathway 503A: HHS draft policyPrice this item

    503A: covered by the HHS draft six-peptide policy (Oct 30, 2026) in the acetate form, by the listed routes, if all 10 conditions are met. Draft, nonbinding.

  • N-Acetyl-BPC-Amidate No 503B pathwayPrice this item

    Outside the HHS 503A draft policy (acetate form only).

  • P-21 Acetate No 503B pathwayPrice this item
  • PE 22-28 Acetate No 503B pathwayPrice this item
  • PEG-MGF Acetate No 503B pathwayPrice this item

    FDA previously listed safety concerns (nomination withdrawn from Category 2).

  • Pentadecapeptide Arginate (BPC-157 Arginate) No 503B pathwayPrice this item

    Outside the HHS 503A draft policy (acetate form only).

  • Pinealon Acetate No 503B pathwayPrice this item
  • Protirelin Acetate No 503B pathwayPrice this item

    503B Category 3 (nominated without adequate support).

  • PTD-DBM Acetate No 503B pathwayPrice this item
  • Rusalatide (TP508) Acetate No 503B pathwayPrice this item
  • Selank Acetate No 503B pathwayPrice this item

    FDA previously listed safety concerns (nomination withdrawn from Category 2).

  • Semax Acetate No 503B pathwayPrice this item

    HHS draft 503A policy lists Semax free base (intranasal), not the acetate.

  • Setmelanotide Acetate No 503B pathwayPrice this item
  • Tesamorelin Acetate No 503B pathwayPrice this item

    44 amino acids; biologic status unverified.

  • Thymosin Alpha-1 Acetate No 503B pathwayPrice this item

    503B Category 3 (nominated without adequate support). Also on the withdrawn-from-Category-2 list.

  • Thymosin Beta-4 Fragment (TB500) Acetate No 503B pathway 503A: HHS draft policyPrice this item

    503A: covered by the HHS draft six-peptide policy (Oct 30, 2026) in the acetate form, by the listed routes, if all 10 conditions are met. Draft, nonbinding.

  • Thymulin Acetate No 503B pathwayPrice this item
  • Vasoactive Intestinal Peptide (VIP) Acetate No 503B pathwayPrice this item
  • α-MSH (Alpha-Melanocyte-Stimulating Hormone) No 503B pathwayPrice this item
  • GHRP-2 Acetate 503B Category 2: FDA safety riskPrice this item

    Category 2 for injectable and nasal use; Category 1 for other routes.

  • Thymosin Beta-4 Acetate Biologic: not compoundablePrice this item

    Treated as a likely biologic (protein over 40 amino acids); FDA has not ruled on this item.

Questions

Which peptides have a 503B route?

None is on the 503B bulks list. Sermorelin, gonadorelin and oxytocin are in 503B Category 1 (interim policy).

What does "FDA previously listed safety concerns" mean?

FDA had placed the substance in Category 2 before its nomination was withdrawn. It has no 503B pathway today.

Do you state the form?

Yes. Salt and form are on every quote line.

Every quote includes

A written price and pack size per item, the lot COA, and each item's FDA status as of the date we price it. Nothing ships until you approve the price sheet.

Request a quote